XIENCE 28 USA Study
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1605 participants.
Also called NCT03815175
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 1,605 participants
- Sponsor
- Registry
-
NCT03815175
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Belgium, Canada, China, Germany, Hong Kong SAR China, Italy, Netherlands, Portugal, Singapore, Spain, Switzerland, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03815175. Allocation not applicable; no masking; primary purpose treatment. Start 2019-02-25 (actual); primary completion 2020-08-14 (actual). Results posted on 2021-12-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- XIENCE 28 USA Study
- Condition
- Bleeding Disorder
- Condition
- Ischemic Stroke
- Condition
- Hemorrhagic Stroke
- Condition
- Hematological Diseases
- Condition
- Thrombocytopenia
- Condition
- Coagulation Disorder
- Condition
- Anemia
- Condition
- Renal Insufficiency
- Condition
- Coronary Artery Disease
- Intervention (Device)
- XIENCE
- Intervention (Drug)
- DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Lead sponsor
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct03815175- Content hash
a2b2d285621b6b023a41652578d2aadc699a7e295841c93afe515b07402fe9af